Alectinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1386 publications
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Journal: Future oncology (London, England)
Published: April 08, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.
Journal: JCO precision oncology
Published: March 30, 2026
Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.
Journal: Chemical research in toxicology
Published: February 27, 2026
Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.
Journal: Journal of chemotherapy (Florence, Italy)
Published: February 23, 2026
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
Journal: Lung cancer management
Published: February 03, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 22, 2026
Evaluation of Drug-Induced Kidney Injury by Primary Culture of Rat Kidney Tissue Slices Using Oxygen-Permeable Polyolefin Plate with Low Drug Adsorption.
Journal: Biological & pharmaceutical bulletin
Published: January 21, 2026
FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.
Journal: Frontiers in oncology
Published: January 16, 2026
A High-Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK-Rearranged Non-Small Cell Lung Cancer.
Journal: Pediatric blood & cancer
Published: January 08, 2026
Last Updated: 04/28/2026